RxDoctor Payments Data

Hernan Salazar, DO

Internal Medicine · San Antonio, TXNPI 1538220892

Payments from drug & device makers

What this record shows

This record is dominated by travel and lodging: $1,130 of the $1,839 with a category attached, or 61.4%. Novartis accounts for 63.5% of it on its own, with 1 other manufacturer making up the rest.

$1,839in general payments, 2019–2025

Across 30 payments — averaging $61.29 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$1K
  • Eli Lilly$672
$18,517,327in research payments, 2019–2025

Across 454 payments — averaging $40,787 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Janssen Research & Development, LLC$6.7M
  • Innocoll Pharmaceuticals Limited$3.2M
  • Heron Therapeutics, Inc.$2.1M
  • Vertex$2M
  • Dexcom, Inc.$1.3M
  • Eli Lilly$976K
  • plus $2.2M from 13 others

What the payments were for

  • Travel & lodging$1,13061%
  • Food & beverage$70939%

General payments by program year

19
20
23

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Novartis9$1,167
Eli Lilly21$672

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,839 in reported general payments places this provider in the 75th percentile of 7,675 internal medicine providers in Texas.

See all internal medicine providers in Texas

Medicare billing

Part B allowed, 2024
$10,971
Medicare patients
13
Services billed
78

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Testosterone Cypionate13$302
Venlafaxine Hcl ErVenlafaxine Hcl15$238
Bupropion XlBupropion Hcl12$142
Levothyroxine Sodium17$122
Irbesartan16$118
Metformin Hcl12$47

Paid to pharmacies, not to this prescriber.

Other internal medicine in San Antonio

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →